anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Pharmaceutical or chemical tablets or pills, and in particular poisonous antiseptic tablets such as those described in Specification 125,054, [Class 81 (i), Disinfecting, &amp;c.], are coated with a material which is insoluble in the digestive juices so as to prevent poisoning if accidently swallowed.  As additional precautions the coating may contain a repulsive tasting substance such as aloes, and a chemically inert dye and gritty material such as sand may be incorporated in the coating or in the body of the tablet.  The coating which may consist of a wax such as paraffin, beeswax, or carnauba wax, of a cellulose product such as collodion, or of resin, is melted and sprayed on during tumbling, or applied in any usual manner.  The tablet is broken to allow it to be dissolved for use or may be coated with a substance which is soluble in a particular solvent such as alcohol.  The coating is stated to prevent deliquescence.  The use of poisonous tablets containing a dye, or of distinctive shape such as square, oblong, or coffin-shaped is referred to.
Solid particles are coated by suspending the particles as a fluidized bed in a gas stream of non-uniform upward velocity such that in one portion of the bed in which the gas stream moves with a relatively high velocity, the particles move upwards substantially out of contact with each other and in that part in which the gas stream moves with a relatively lower velocity, the particles move downwards in substantially weightless contact with each other, the coating materials being introduced into the gas stream at the lower end of the upwardly flowing part of the bed. For producing nonuniformity of gas velocity grids or screens of non-uniform aperture size or in which the &#34;mesh&#34; only covers a portion of the conduit may be placed in the gas conduit.  These may be replaced or used in combination with movable &#34;damper&#34; plates.  The coating compositions used may be liquids or finely-divided solids, e.g. aqueous sugar solutions and compositions comprising film-forming substances, e.g. polyvinyl alcohol, cellulose acetate phthalate and zein, natural and synthetic resins, e.g. shellac, alkyl and silicone resins, waxes and waxy materials, e.g. polyvinyl pyrrolidone, glyceryl monostearate and glyceryl monostearate, plasticizing agents, colouring agents and bulking substances, e.g. starch, talc or magnesium carbonate.ALSO:Solid particles, e.g. medicinal tablets, are coated by suspending the particles in an upwardly flowing gas stream containing coating material and causing circulation of the particles in the fluidized bed by directing the gas stream through one portion of the bed at a higher velocity than through another portion, the gas velocity being such that the particles flow upwards in the high velocity region and flow downwardly in weightless contact in the region of lower velocity, the particles p  in the upward flowing region being substantially out of contact with each other.  The coating materials are directed into the lower end of the upwardly flowing gas stream and for causing the variable gas flow velocity, there may be used grids or screens in which the size of the openings is not uniform or in which the mesh only partially covers the gas conduit in which they are placed beneath the fluidized bed and which may be replaced or used in combination with movable &#34;damper&#34; plates.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a heating implement which has excellent cooling sensation in use and prevents deterioration of the cooling sensation during storage.  &lt;P&gt;SOLUTION: The heating implement 100 comprises a heat generating part 121 containing metal to be oxidized and activated carbon, and a bag body 110 at least a part of which has gas permeability and which stores the heat generating part 121. The heating implement 100 is perfumed by a scent composition containing the component A and component B. The ratio of total mass of the component A and the component B to the mass of the activated carbon [(component A+component B)/activated carbon] is 0.04 to 0.2. The scent composition is preferably given between the heat generating part 121 and the bag body 110. The &#34;component A&#34; is a monoterpenoid having a cyclic ether structure. The &#34;component B&#34; is a monoterpenoid having a cyclic ketone structure.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To provide an agent giving blood coagulation-inhibitory activity when acting on the blood coagulation system, also giving antineoplastic activity, effective for solid carcinomas. CONSTITUTION:The objective antineoplastic agent containing, as active ingredient, a 7-hydroxy-8-methoxy-5-methylbenzo[c]phenanthridinium of the formula (X&lt;-&gt; is acid residue). The agent gives excellent antineoplastic activities (e.g. inhibitory activity against platelet coagulation by platelet-activating factor which is considered to be involved in the proliferation inhibitory effect on cancer cells and the matastasis), being effective for solid carcinomas such as stomach cancer, ovarian cancer, hepatoma, rectal cancer, and lung cancer, or leukemia. The agent can be administered through injection or the rectum, or perorally; the content of the above compound in the pharmaceutical preparation is normally 0.01-100 (pref. 0.1-50)wt.%, and the dosage of this compound is ca.50-500mg per adult a day.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide new compositions and methods for preventing and treating pathogen infection.  &lt;P&gt;SOLUTION: There are disclosed therapeutic compositions that have an anchoring domain that anchors compounds to the surface of a target cell and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen such as virus and have sialidase activity, including protein-based compounds having sialidase catalytic domains. The compounds can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. There are also disclosed compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE: To obtain a cosmetic, having high humectant effects with persistence and effective in caring for the skin or hair. CONSTITUTION: This cosmetic contains 1-50wt.% phosphoric triester of the formula (R&lt;1&gt; to R&lt;3&gt; are each a &gt;=11C alkyl, with the proviso that at least one of R&lt;1&gt; to R&lt;3&gt; is &gt;=13C and at least one is a branched alkyl) and 2-90wt.% polyol- based humectant (e.g. dipropylene glycol). The mixing ratio of the compound of the formula to the polyol-based humectant is preferably about 1/2. Furthermore, both the ingredients are blended with a hydrophilic humectant ingredient having &gt;=10wt.% solubility in the polyol-based humectant at 20 deg.C (e.g. glycerol) and an optional ingredient such as an oil, a surfactant or an ultraviolet absorber and prepared into an oily, an emulsified or a water-based cosmetic. The cosmetic is especially suitable as a skin or a hair cosmetic requiring humectant effects such as caring for rough skin, hair, etc.
Light at a therapeutic wavelength is applied to a patient&#39;s blood while that blood remains in the body. A port is surgically implanted in the patient. A UV pack or a UV device is connectable to the port. The UV pack has a battery or other power supply and a UV light source. The UV light source is typically LEDs. The UV pack is connected to the port via a tube or catheter. A fiber optic strand or bundle runs through the tube to provide the UV light to the blood. Similarly, the UV device is connected to the port via a tube or catheter. A fiber optic bundle or other light guide directs the light to the blood.
The invention relates to a programmed-drug-release azobenzene derivative carrier, and a preparation method and application thereof. One end of azobenzene and derivative thereof of the carrier compound is connected with a cholesteryl group, and the other end is connected with a nitrogen heterocycle group. The chemical structural formula is disclosed in the specification, wherein R is alkyl group, aromatic ring group or H, R&#39; is C1-3 alkyl group or H, n=1 or 2, and x=2-10. The preparation method comprises the following steps: diazo coupling, substitution, esterification, azanylation and the like. The novel azobenzene derivative can be used in the aspects of programmed-drug-release carriers and other photosensitive or temperature-sensitive stimulus-responsive materials. Compared with the prior art, the method provided by the invention is simple and easy to implement; and the prepared compound can be used in programmed-drug-release carriers and other photosensitive or temperature-sensitive stimulus-responsive materials, and has wide application prospects.
PURPOSE:To safely and stably obtain a human type antibody useful for measuring antigenic substances, etc., by cultivating an animal cell transformed by a specific recombinant. CONSTITUTION:A vector pG31VK-neo containing a human type antibody L-chain (two light chains) gene is introduced into an animal cell P3U1 to provide a transformant 26-103. A vector pG3101 (gamma1) containing H-chain (two heavy chains) gene is then introduced into the transformant 26-103 to afford a transformant G3101-F. Cells of the resultant transformant are subsequently inoculated into a complete culture medium prepared by adding bovine fetal blood serum to an RPMI-1640 culture medium, etc., and cultivated. The resultant culture is separated to afford a supernatant, which is then treated with (NH4)2SO4, etc., to provide protein precipitates. The obtained protein is purified by an ion exchanger, gel filtration, etc., to isolate a human type antibody, such as IgG1 or IgG3, corresponding to Fischer&#39;s serotype classification type 4 (F4) of Pseudomonas aeruginosa.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a navel depression-cleaning agent capable of easily removing bellybutton lint, etc., at the navel without harming the inner surface of the navel depression, and a method for cleaning the navel depression by using the same.  &lt;P&gt;SOLUTION: This navel depression-cleaning agent comprises a film-forming water soluble polymer and a water-absorbent. The weight ratio of the water soluble polymer to the water absorbent (the former to the latter) is preferably (100:1) to (1:5). The water soluble polymer is preferably polyvinyl alcohol or polyvinyl pyrrolidone, and the water absorbent is preferably a highly absorbable polymer. The method for cleaning the navel depression by using the navel depression-cleaning agent is provided by supplying a mixture of the navel depression-cleaning agent and a water-containing volatile medium to the nave depression and after drying and solidifying the cleaning agent, taking out the film consisting of the solidified material from the navel depression in a state of accompanying the soil in the navel depression.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To readily and effectively control occurrence of a bad habit of picking other fowl&#39;s buttock, by adding a specific amount of free-form L-tryptophan or a salt thereof to a feed for domestic fowl. CONSTITUTION:Free-form L-tryptophan or a salt thereof, e.g. mineral acid salt or alkali metal salt, is added to a feed ordinarily given to domestic fowl to control occurrence of a habit of picking other domestic fowl&#39;s buttock. The preferred amount of addition is normally about 0.001-2wt% based on the feed. The occurrence of bad habit of picking other domestic fowl&#39;s buttock can be controlled without requiring a skilled hand. As a result, deterioration in mortality and egg production ratio of domestic fowl by this bad habit, etc., can be prevented.
New concept was developed for formation of human- and environmental- friendly material able to provide antibacterial activity. This material is composed of bioceramic (hydroxyapatite), metallic (gold) and organic part containing amino and thiol groups (amino acids) in the form of composite. Bioceramic part of this material is templating agent applied as a controller of growth and stability of metallic nanoparticles particle. These metallic nanoparticles have functionalized surface and they are centers of antibacterial activity of composites. Efficacy of antibacterial activity of these materials depends on selection of surface functionalization providing activity against both Gram-positive and Gram-negative bacteria. For developed materials this activity is much stronger compare to HAp/Ag composite which shows ability for their use as more favorable replacement of toxic silver. Materials were synthesized using sonochemical method, which has been developed as a novel, &#34;green&#34; approach for their formation.
&lt;P&gt;PROBLEM TO BE SOLVED: To produce porphyran from dried laver while remarkably decreasing the energy consumption necessary for the heating of laver, reducing the size of the production facility to reduce the installation cost, and increasing the production efficiency to reduce the production cost e.g. by shortening the production time and provide porphyran at a reduced price.  &lt;P&gt;SOLUTION: Discolored dry laver is put into a closeable bottle and steamed until the laver is completely changed to green color. Water is added to the heat-treated dry laver and the obtained fluid is left at rest in a vessel. The fluid is separated into an extracted liquid containing porphyran and a residue by solid-liquid separation with a centrifugal separator, and the extracted liquid is filtered with a ceramic filter to obtain a concentrated extracted liquid. The concentrated extracted liquid is charged into a spray drier to obtain pulverized porphyran.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a lipid metabolism improving agent useful as a medicine or a food that has inhibitory effect on cholesterol absorption or excretion effect on bile acid and reduces blood cholesterol.  &lt;P&gt;SOLUTION: The lipid metabolism improving agent comprises a krill protein as an active ingredient. The medicine or food comprises the same. The functional food for improving lipid metabolism comprises a krill protein as an active ingredient. The functional food for improving lipid metabolism is effective for improving lipid metabolism.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To obtain the subject safe and effective suppressant containing at least one kind selected from vitamin D3 and its derivatives. CONSTITUTION:This synovial proliferation suppressant comprises at least one kind selected from vitamin D3 and its derivatives. Vitamin D3, which is the main component constituting vitamin Ds found in foods such as fish liver, fish meat, butter or yolk, is isolated from these foods. Also, vitamin D3, when taken in vivo, is metabolized into activated type 1,25-hydroxycholecalciferol and exhibits physiological activity. The therapeutic agent for chronic articular pheumatism contains this preparation as active ingredient. The does of this therapheutic agent is &gt;=0.0125-1.0mug a day per adult in terms of vitamin D3 or its derivative.
The invention belongs to the field of genetic engineering, discloses a streptococcus thermophilus derived target sequence recognizable by a CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated 9) system and further discloses a sgRNA (single guide ribonucleic acid) and a coding DNA (deoxyribonucleic acid) molecule thereof. The target sequence is shown as n-20th of any one of SEQ ID NO:1-63, wherein n=1-5. A sequence of the sgRNA is 5&#39;-recognition sequence- Cas9 protein recruitment sequence-3&#39;, and a DNA sequence corresponding to the recognition sequence is identical to the target sequence. The invention also discloses the CRISPR-Cas9 system, and the CRISPR-Cas9 system comprises Cas9 proteins and sgRNA and/or comprises carriers carrying a Cas9 protein coding sequence and a sgRNA coding sequence. The invention further discloses application of the CRISPR-Cas9 system to CXCR4 gene editing and preparation of medicines for treating HIV (human immunodeficiency virus) infection. CXCR4 gene editing can be realized to protect cells from HIV infection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new non-human animal useful for screening therapeutic and/or prophylactic drugs for psychiatric disorders including mania, depression, manic-depressive, hyperkinetic disorders, autism, schizophrenia and post-traumatic stress disorders or dysmnesia including learning one and ones associated with aging, cerebrovascular disorders, dementia, Parkinson&#39;s disease and depression.  &lt;P&gt;SOLUTION: The non-human animal that is transferable is such that activin gene is overexpressed at least in its brain, and has at least either one phenotype among activity elevation, emotion abnormality, information processing mechanism abnormality and learning dysmnesia. The offsprings thereof are also provided. Another version of this non-human animal that is transferable is such as to be transferred with activin gene under the control of a promoter activated at least in its brain. The offsprings thereof are also provided.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
NEW MATERIAL:A tris[N-substituted-2-aminoethyl]amine-iron complex expressed by formula I [R is expressed by formula II (R&lt;1&gt; is lower alkyl or lower alkoxycarbonyl), expressed by formula III, expressed by formula IV or expressed by formula V]. USE:Used as medical drug useful for remedy of various symptoms owing to active oxygen species, e.g. inflammatory disease (chronic rheumatism or collagen disease, etc.), chronic dermatosis, arterial sclerosis, medicinal poisoning or radiation damage, etc., having active oxygen-eliminating action with excellent stability in administration into live body without suffering to activity inhibition by serum albumin. PREPARATION:Chelate bonding is formed with N in 1 mol tetramine compound and 1mol iron to afford the aimed compound expressed by formula I. For instance, 3-methylpyridine-2-aldehyde is obtained from reaction product of 2,3- lutidine and iodine, then dissolved in methanol, thus refluxed with heating under argon gas current and reduced to obtain the teramine compound.
PCT No. PCT/JP94/00233 Sec. 371 Date Apr. 24, 1995 Sec. 102(e) Date Apr. 24, 1995 PCT Filed Feb. 16, 1994 PCT Pub. No. WO94/19375 PCT Pub. Date Sep. 1, 1994Heat resistant carbonate- and/or hydrogencarbonate-iron-Lf complexes in which one molecule of lactoferrin is bound with 15 molecules or over of iron via carbonic acid and/or hydrogencarbonic acid. Process for the production of above mentioned complexes prepared by adjusting pH&lt;/=7 by adding alkali salts of carbonic acid and/or hydrogencarbonic acid to an aqueous solution containing an iron salt exhibiting pH&lt;/=4 when dissolved in water and lactoferrins, or adding an iron salt and lactoferrin solution to carbonic acid and/or hydrogencarbonic acid solution, or adding the iron salt or its solution to a solution containing carbonic acid and/or hydrogencarbonic acid and lactoferrins. The resultant lactoferrin complexes are highly heat resistant and useful as raw materials of foods, medicines, feeds, cosmetics and so forth.
The present invention relates to a medicinal herb composition for suppressing obesity which effectively reduces body weight without side effects to a human body and is able to prevent various diseases caused by overweight or obesity. The medicinal herb composition for suppressing obesity according to the present invention contains Ephedra sinica, Atractylodes japonica, Coix lachryma-jobi L. var. ma-yuen Stapf, Rehmannia glutinosa, Crataegus pinnatifida Bunge var. typica Schneider, corn silk, pine needles, Dimocarpus longan Lour., and Poria cocas Wolf. and further contains Sinomenium acutum (Thunb.) Rehder&amp;amp; E.H.Wilson, Citrus unshiu Markovich, Acyranthes bidentata Blume, Angelica gigas Nakai, Caesalpinia sappan L., Artemisia asiatica, Cartami semen, Acanthopanax sessiliflorum, Astragalus membranaceus BUNGE, and Glycyrrhiza uralensis Fischer.
PURPOSE:To obtain a nontoxic bathing agent, containing an extract solution prepared by extracting the tree bark of Quillaia saponaria Mol. with a solvent consisting essentially of water or a lower alcohol and having great detergency with treating effects on dermatosis, atopic diseases or pimple and further sound sleep effects. CONSTITUTION:A bathing agent obtained by crushing the tree bark of Quillaia saponaria Mol. into a chip form, dipping the resultant chips in a solvent consisting essentially of water or a lower alcohol (e.g., methanol, ethanol, ethylene glycol or glycerol), heating the dipped chips, filtering the solvent to provide an extract solution (30-35% concentration) and containing the obtained extract solution therein. Since the above-mentioned bathing agent has great detergency and requires no washing of human bodies or bathtubs, the agent is greatly advantageous to persons of disabled bodies or the aged. The agent has treating effects on dermatosis, the ability to soundly sleep, etc., further prevention of reduction in hot water temperature and decrease in temperature difference between the upper and lower parts of hot water. The optimum amount of the agent used is 5-20cc expressed in terms of stock extract solution of the Quillaia saponaria Mol. based on 1m&lt;3&gt; hot water.
A method and composition are presented for enhancing the dissolution and bioavailable properties of CoQ10 nutritional supplements and/or therapeutic agents for a human being and other mammals. The method includes preparing an anhydrous self~microemulsifying base composition by combining: CoQ10, a water-immiscible, and a non-ionic surfactant, containing polyethylene glycol. For an orally administered CoQ10 nutritional supplement in a capsule formulation, a unit dosage from the composition is added to a dissolvable capsule, preferably a soft gelatin capsule, in order to form the nutritional supplement. When a capsule containing the self-microemulsifying composition enters the digestive tract, the temperature of the body&#39;s digestive juices warms the composition, causing any of the CoQ10 that may have re-crystallized out of the composition to become re-dissolved into the composition before the capsule dissolves. The re-dissolution of CoQ10 is bioavailable when the capsule dissolves. Upon dissolution of the capsule, the self-microemulsifying composition comes into contact with the digestive juices and naturally forms micellar-type bioavaible microemulsions, consisting of micelles containing CoQ10. In addition to the capsule formulation, the invention includes parenteral, liquid, topical and ophthalmic formulations.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a transport apparatus having a means for shaking a blood preparation, especially a platelet-based preparation during its transportation.  &lt;P&gt;SOLUTION: The transport apparatus 1 for the blood preparation comprises a thermal insulation container 3 for transporting, a temperature control unit 4 as a temperature control means for keeping the thermal insulation container 3 at a predetermined temperature, and a shaking unit 5 as a shaking means installed in the thermal insulation container 3. In this apparatus 1, the shaking unit 5 has a substrate 13 as the base, wherein the respective dimensions L1 and W1 in the cross direction and the depth direction on the horizontal surface of the substrate 13 are nearly equal to those L2 and W2 on the inner bottom surface of the transport house 3. Thus, by operating the shaking unit 5, the function of the platelet-based preparation P can be maintained. Besides, with a combination of the shaking unit 5 with the single-purpose thermal insulation container 3, by shaking the platelet-based preparation P under a predetermined container temperature condition, the optimal quality maintenance for the platelet-based preparation P can be accomplished.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT